Black Diamond Therapeutics (NASDAQ:BDTX) Price Target Cut to $11.00 by Analysts at HC Wainwright

Black Diamond Therapeutics (NASDAQ:BDTXFree Report) had its price target decreased by HC Wainwright from $12.00 to $11.00 in a research note released on Thursday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Black Diamond Therapeutics’ Q1 2025 earnings at ($0.46) EPS, Q2 2025 earnings at ($0.49) EPS, Q3 2025 earnings at ($0.51) EPS and Q4 2025 earnings at ($0.54) EPS.

Separately, Wedbush boosted their price target on shares of Black Diamond Therapeutics from $10.00 to $16.00 and gave the company an outperform rating in a report on Monday, April 8th.

View Our Latest Analysis on BDTX

Black Diamond Therapeutics Stock Performance

NASDAQ BDTX opened at $4.87 on Thursday. Black Diamond Therapeutics has a twelve month low of $1.57 and a twelve month high of $7.66. The stock has a market cap of $273.94 million, a PE ratio of -2.93 and a beta of 2.56. The firm has a 50-day simple moving average of $5.37 and a 200 day simple moving average of $3.94.

Black Diamond Therapeutics (NASDAQ:BDTXGet Free Report) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.09. Research analysts forecast that Black Diamond Therapeutics will post -1.47 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Black Diamond Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Bellevue Group AG raised its stake in Black Diamond Therapeutics by 4.9% during the fourth quarter. Bellevue Group AG now owns 8,535,839 shares of the company’s stock worth $23,986,000 after acquiring an additional 400,000 shares in the last quarter. Barclays PLC grew its holdings in shares of Black Diamond Therapeutics by 159.1% in the 3rd quarter. Barclays PLC now owns 322,246 shares of the company’s stock worth $925,000 after purchasing an additional 197,895 shares during the last quarter. Cornercap Investment Counsel Inc. acquired a new stake in shares of Black Diamond Therapeutics during the 4th quarter worth about $233,000. Citigroup Inc. bought a new position in Black Diamond Therapeutics during the 3rd quarter valued at about $176,000. Finally, Pale Fire Capital SE acquired a new position in Black Diamond Therapeutics in the fourth quarter valued at about $144,000. Institutional investors own 95.47% of the company’s stock.

About Black Diamond Therapeutics

(Get Free Report)

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.

Featured Stories

Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with's FREE daily email newsletter.